logo
Search orAI Icon𝛼SK
ENTITY
Abbisko Cayman

Abbisko Cayman (2256 HK)

26
Analysis
Health Care • China
Abbisko Cayman Limited operates as a biopharmaceutical company. The Company dedicated to the discovery and development of innovative and differentiated small molecule incology therapies. Abbisko Cayman provides services in China.
more
Exchange Announcement • 16 Dec 2025 08:00

Voluntary Announcement - Abbisko Therapeutics Completes First Patient Dosing Of Absk061, Fgfr2/3 Inhibitor, For The Treatment Of Achondroplasia

Exchange Announcement • 08 Dec 2025 08:00

Voluntary Announcement - Abbisko Therapeutics Presents Preliminary Phase Ii Results Of Oral Pd-L1 Inhibitor Absk043 Combined With Egfr Inhibitor Firmonertinib For The Treatment Of Nsclc At Esmo Asia 2025

Exchange Announcement • 01 Dec 2025 17:39

Voluntary Announcement - Ind Clearance From The Fda For Oral Small Molecule Kras G12d Inhibitor Absk141

Exchange Announcement • 17 Nov 2025 08:00

Voluntary Announcement - Abbisko Therapeutics Presents Longer-Term Efficacy And Safety Outcomes From Phase Iii Maneuver Study Of Pimicotinib At Ctos 2025 Annual Meeting

Exchange Announcement • 03 Nov 2025 08:00

Voluntary Announcement - Abbisko Therapeutics Completes First Patient Dosing In A Phase Ii Study Of Absk043, An Oral Small-Molecule Pd-L1 Inhibitor, In Combination With Glecirasib For The Treatment Of Nsclc

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.60.3

x